Targeting serious intestinal disease at its source



About us

Curileum is a discovery stage company in London targeting defective mucosal stem cells that underpin serious gastrointestinal (GI) diseases and disorders with major GI complications.

Targeting serious GI disease at its source

We are discovering novel targets and drugs to correct imbalances in cell number and composition of the mucosal barrier – eliminating precancerous cells and dampening chronic inflammation in IBD and obesity – rather than treating the consequences of disease development.

“Curileum is partnering with pharmaceutical companies to discover and develop new drugs to restore health to the gut barrier, protecting against the consequences of harmful bacteria and chronic disease.”

Jeff Moore
Founder & CEO

Our approach

We discover and validate novel therapeutic targets by comparing the in vitro properties of stem cells from healthy and diseased intestinal tissues to reveal the triggers of cell production and new targets for intervention.



The problem

Degradation of the single cell lining of the intestine leads to disease. Bacterial toxins permeate mucosal tissue and activate potent inflammatory responses.

Our solution

Instead of treating disease symptoms in the $35bn gastrointestinal market, Curileum is targeting stem cells to correct imbalances in the numbers and functions of cells to restore intestinal health.

Learn more about our discovery platform

Therapeutic areas

Seal The Mucosal Barrier

Harmful bacteria and chronic disease degrade the mucosal barrier

Diabetes and obesity

Kill Defective Stem Cells

Chronic inflammation and ageing can select for defective stem cells

Inflammatory bowel disease

Increase Gut Motility

Reduced pacemaker cells and chronic inflammation leads to slow motility

Diabetes and obesity

Contact Us

If you’re interested in finding out further details regarding our stem cell drug discovery and development work then get in contact with us.

    *Required fields

    I am not a robot